Insider Transactions in Q1 2024 at Harpoon Therapeutics, Inc. (HARP)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2024
|
Scott Dunseth Myers |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,665
-100.0%
|
-
|
|
Mar 11
2024
|
Luke Nathaniel Walker Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
135,000
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,859,169
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,224
-100.0%
|
-
|
|
Mar 11
2024
|
Lauren P Silvernail |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
395,783
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,463,386
-100.0%
|
-
|
|
Mar 11
2024
|
Mark Chin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,224
-100.0%
|
-
|
|
Mar 11
2024
|
Joseph S Bailes |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
Julia Marie Eastland President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
269,381
-100.0%
|
-
|
|
Mar 11
2024
|
Julia Marie Eastland President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+10.39%
|
-
|
|
Mar 11
2024
|
Frank J Lanza Principal Fin. & Acctng Ofc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,734
-100.0%
|
-
|
|
Mar 11
2024
|
Andrew R Robbins |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
Jonathan G Drachman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,415
-100.0%
|
-
|
|
Mar 11
2024
|
Merck & Co., Inc. |
BUY
Open market or private purchase
|
Indirect |
21,397,205
+100.0%
|
$492,135,715
$23.0 P/Share
|
|
Mar 08
2024
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
424
+3.11%
|
-
|
|
Mar 08
2024
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
424
+3.11%
|
-
|
|
Mar 08
2024
|
Jonathan G Drachman |
BUY
Grant, award, or other acquisition
|
Direct |
415
+7.12%
|
-
|
|
Jan 07
2024
|
Julia Marie Eastland President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
178,500
+43.48%
|
-
|
|
Jan 07
2024
|
Frank J Lanza Principal Fin. & Acctng Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+44.96%
|
-
|
|
Jan 07
2024
|
Luke Nathaniel Walker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+46.0%
|
-
|
|
Jan 01
2024
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
1,072
+7.73%
|
-
|
|
Jan 01
2024
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
1,072
+7.73%
|
-
|
|
Jan 01
2024
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
2,048
+8.29%
|
-
|